Carotuximab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | endoglin |
Clinical data | |
Other names | TRC-105 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6420H9922N1718O2010S46 |
Molar mass | 144808.77 g·mol−1 |
Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
This drug was developed by Tracon Pharmaceuticals Inc.[2]
It is at Phase III trials for angiosarcoma.
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Monoclonal antibodies